Anbio Biotechnology
NNNNHealthcareNASDAQMedical Instruments & Supplies · Last scanned Oct 24, 2026
Scan Results
Daily timeframeAnbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. At a $167.2M market cap, Anbio Biotechnology ranks as a micro-cap company within healthcare. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Market Cap
$167.2M
Beta
—
P/E (TTM)
25.40
P/E (Fwd)
—
EPS (TTM)
$0.15
EPS (Fwd)
—
ROE
27.1%
ROA
14.7%
Cash
$11.9M
Total Debt
$0
Free CF
-$9.6M
52W Change
-83.4%
Annual Financials
Cash vs Debt
Where NNNN stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, NNNN finished 79.64% below its 150-day moving average ($16.06) and 82.54% below its 200-day moving average ($18.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NNNN overbought or oversold?
At the October 20, 2026 close, NNNN's RSI(14) was 10.6, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Anbio Biotechnology reports $11.9M in cash and $0 in total debt. Free cash flow is running at -$9.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 27.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 14.7% further supports the picture of efficient asset utilization. Revenue has been uneven over recent years, ranging from $23.5M to $8.6M.
Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Anbio Biotechnology and its sector.